FDA approves Sanofi's Jevtana for prostate cancer; Amgen looks for acquisitions;

 @FierceBiotech: EXCLUSIVE: Pfizer plans to move fast on rare disease pacts. Story | Follow @FierceBiotech

 @JohnCFierce: GW is developing Sativex (with Otsuka) for cancer pain in the US; significantly more lucrative than the MS approvals it's getting in Europe. | Follow @JohnCFierce

> The FDA has approved Sanofi-Aventis' prostate cancer injection Jevtana (cabazitaxel). The drug is used combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen. Sanofi release

> Amgen is "aggressively" looking at acquisitions, particularly opportunities for international expansion, Chief Executive Kevin Sharer said. Report

> Genzyme has entered into an agreement with Goldman Sachs to repurchase $1 billion of Genzyme common stock. Genzyme release

And Finally... Women who drink tea have an increased risk of developing Rheumatoid Arthritis compared with those who drink none, according to Georgetown University Medical Center study. Release